ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL723
CHEMBL723
Compound Name CARVEDILOL
ChEMBL Synonyms EUCARDIC 12.5 | SK&F-105517-D | EUCARDIC 6.25 | Coreg CR | CARVEDILOL | BM 14.190 | BM-14.190 | Carvedilol phosphate | BM-14-190 | COREG | EUCARDIC 25 | EUCARDIC 3.125 | COREG CR
Max Phase 4 (Approved)
Trade Names COREG CR | EUCARDIC 3.125 | COREG | EUCARDIC 25 | EUCARDIC 12.5 | CARVEDILOL | Coreg CR | EUCARDIC 6.25
Molecular Formula C24H26N2O4

Additional synonyms for CHEMBL723 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES COc1ccccc1OCCNCC(O)COc2cccc3[nH]c4ccccc4c23
Standard InChI InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15- ...
Download InChI
Standard InChI Key OGHNVEJMJSYVRP-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Curated Drug Pharmacokinetic Data
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL723

Molecule Features

CHEMBL723 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Racemic Mixture Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Adrenergic receptor alpha-1 antagonist Adrenergic receptor alpha-1 FDA
Adrenergic receptor beta antagonist Adrenergic receptor beta FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Leukemia, LymphoidD007945EFO:0004289lymphoid leukemia3ClinicalTrials
NeoplasmsD009369EFO:0000311cancer2ClinicalTrials
Stress Disorders, Post-TraumaticD013313EFO:0001358post-traumatic stress disorder2ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma2ClinicalTrials
ClinicalTrials
Heart FailureD006333EFO:0000373congestive heart failure3ClinicalTrials
ClinicalTrials
Hypertrophy, Left VentricularD017379EFO:0003896left ventricular hypertrophy3ClinicalTrials
LymphomaD008223EFO:0000574lymphoma3ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma3ClinicalTrials
Hypertension, PulmonaryD006976EFO:0001361pulmonary hypertension2ClinicalTrials
Ventricular Dysfunction, LeftD018487EFO:0000537hypertension4FDA
FDA
EpilepsyD004827EFO:0000474epilepsy2ClinicalTrials
Atrial FibrillationD001281EFO:0000275atrial fibrillation3ClinicalTrials
HypertensionD006973EFO:0000537hypertension4ClinicalTrials
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma2ClinicalTrials
Tobacco Use DisorderD014029EFO:0003768nicotine dependence2ClinicalTrials
Vascular DiseasesD014652EFO:0004264vascular disease1ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease4ATC
Hypertension, PortalD006975EFO:0000666portal hypertension3ClinicalTrials
Ventricular Dysfunction, LeftD0184874DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
Cocaine-Related DisordersD019970EFO:0002610cocaine dependence2ClinicalTrials
Essential HypertensionD000075222EFO:1002032primary hypertension3ClinicalTrials
Heart FailureD006333EFO:0003144heart failure3ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia3ClinicalTrials

Clinical Data

ClinicalTrials.gov CARVEDILOL
The Cochrane Collaboration CARVEDILOL

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL723. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL210 Beta-2 adrenergic receptor Homo sapiens 1.000
CHEMBL213 Beta-1 adrenergic receptor Homo sapiens 1.000
CHEMBL246 Beta-3 adrenergic receptor Homo sapiens 1.000
CHEMBL3252 Beta-1 adrenergic receptor Rattus norvegicus 1.000
CHEMBL214 Serotonin 1a (5-HT1a) receptor Homo sapiens 1.000
CHEMBL315 Alpha-1b adrenergic receptor Rattus norvegicus 0.995
CHEMBL289 Cytochrome P450 2D6 Homo sapiens 0.987
CHEMBL313 Serotonin transporter Rattus norvegicus 0.986
CHEMBL3459 Serotonin 1b (5-HT1b) receptor Rattus norvegicus 0.948
CHEMBL4302 P-glycoprotein 1 Homo sapiens 0.919
CHEMBL228 Serotonin transporter Homo sapiens 0.910
CHEMBL273 Serotonin 1a (5-HT1a) receptor Rattus norvegicus 0.368



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL210 Beta-2 adrenergic receptor Homo sapiens 1.000
CHEMBL213 Beta-1 adrenergic receptor Homo sapiens 1.000
CHEMBL246 Beta-3 adrenergic receptor Homo sapiens 1.000
CHEMBL3252 Beta-1 adrenergic receptor Rattus norvegicus 1.000
CHEMBL214 Serotonin 1a (5-HT1a) receptor Homo sapiens 1.000
CHEMBL315 Alpha-1b adrenergic receptor Rattus norvegicus 0.996
CHEMBL3459 Serotonin 1b (5-HT1b) receptor Rattus norvegicus 0.994
CHEMBL4302 P-glycoprotein 1 Homo sapiens 0.974
CHEMBL289 Cytochrome P450 2D6 Homo sapiens 0.935
CHEMBL313 Serotonin transporter Rattus norvegicus 0.842
CHEMBL228 Serotonin transporter Homo sapiens 0.815
CHEMBL2289 Beta-2 adrenergic receptor Canis lupus familiaris 0.479
CHEMBL273 Serotonin 1a (5-HT1a) receptor Rattus norvegicus 0.382

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
406.5 406.1893 3.74 10 75.74 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 3 0 6 3 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
13.9 8.24 4.07 3.06 4 30 0.35

Structural Alerts

There are 2 structural alerts for CHEMBL723. To view alerts please click here.

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C07 - BETA BLOCKING AGENTS
C07A - BETA BLOCKING AGENTS
C07AG - Alpha and beta blocking agents
C07AG02 - carvedilol

ChemSpider ChemSpider:OGHNVEJMJSYVRP-UHFFFAOYSA-N
DailyMed carvedilol carvedilol phosphate
PubChem SID: 26719722 SID: 26719723 SID: 50112972 SID: 50112973 SID: 90341342
Wikipedia Carvedilol

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL723



ACToR 107741-96-8 72956-09-3
BindingDB 25759
Brenda 24148
ChEBI 3441
ChemicalBook CB8351959
DrugBank DB01136
DrugCentral 522
eMolecules 901524
EPA CompTox Dashboard DTXSID8022747
Guide to Pharmacology 551
Human Metabolome Database HMDB0015267
IBM Patent System 9382E5C31F225BF1B47DF79D535D2EF1 4A112BB9168EF4DDB4A47828C5851623
KEGG Ligand C06875
LINCS LSM-1310
Mcule MCULE-7944987271
MolPort MolPort-003-666-814
NIH Clinical Collection SAM001246736
Nikkaji J33.955E
PharmGKB PA448817
PubChem 2585
PubChem: Drugs of the Future 12013067
PubChem: Thomson Pharma 14855122
Selleck carvedilol
SureChEMBL SCHEMBL22293

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/OGHNVEJMJSYVRP-UHFFFAOYSA-N spacer
spacer